文档介绍：HPS: Heart Protection Study
Purpose To determine whether simvastatin reduces mortality and vascular events in patientsents
History of coronary disease
Other risk factors in absence of coronary diseasea
Peripheral arterial disease
% of total
Some patients had more than one of these conditions.
HPS Collaborative Group.
HPS: Heart Protection Study- RESULTS -
All-cause mortality in simvastatin group significantly reduced compared with placebo (12.9 vs. 14.7%, P<0.0003); reduction was attributed largely to significant reduction in coronary death: Other vascular death reduced but with marginal significance Nonvascular death reduced but not significantly First major vascular event rate significantly reduced, as were the individual event rates (fatal/nonfatal MI, fatal/nonfatal stroke, and revascularization) No difference in new cancers (7.9 vs 7.8%, rate ratio 1.0, P=0.9) except nonmelanoma skin cancer (2.4 vs 2.0%) No difference in withdrawal due to myopathy (0.5% in both groups)
HPS: Heart Protection Study- RESULTS continued -
Subtotal: any vascular